# KMC: Evidence, gaps and ongoing research

Department of Maternal, Newborn, Child and Adolescent Health WHO, Geneva





#### **WHO** recommendations



World Health Organization research for Impact

7.0. Kangaroo mother care is recommended for the routine care of newborns weighing 2000 g or less at birth, and should be initiated in health-care facilities as soon as the newborns are clinically stable. **Strong recommendation** based on moderate-quality evidence

7.1. Newborns weighing 2000 g or less at birth should be provided as close to continuous Kangaroo mother care as possible.

**Strong recommendation** based on moderate-quality evidence

7.2. Intermittent Kangaroo mother care, rather than conventional care, is recommended for newborns weighing 2000 g or less at birth, if continuous Kangaroo mother care is not possible.

On moderate-quality evidence







### **Evidence: mortality**

Kangaroo mother care to reduce morbidity and mortality in low birthweight infants (Review)

Conde-Agudelo A, Díaz-Rossello JL

### KMC improves survival of small babies by 40% compared with conventional newborn care

	KMC		Contr	ol		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	<b>Events</b>	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	Quality
1.1.1 All studies								-
Boo 2007	1	65	1	63	2.2%	0.97 [0.06, 15.16]		
Cattaneo 1998	3	149	3	136	6.9%	0.91 [0.19, 4.45]		
Charpak 1997	6	364	10	345	22.5%	0.57 [0.21, 1.55]		
Ghavane 2012	0	68	0	68		Not estimable		
Kadam 2005	1	44	1	45	2.2%	1.02 [0.07, 15.85]		
Rojas 2003	2	33	1	27	2.4%	1.64 [0.16, 17.09]	-	⊕⊕⊕⊕
Suman 2008	1	103	5	103	10.9%	0.20 [0.02, 1.68]		HIGH
Worku 2005	14	62	24	61	52.9%	0.57 [0.33, 1.00]	-	111011
Subtotal (95% CI)		888		848	100.0%	0.60 [0.39, 0.92]	•	
Total events	28		45					
Heterogeneity: Chi <sup>2</sup> :	= 2.29, df=	6 (P=	0.89);	= 0%				
Test for overall effect	t: Z = 2.32	(P = 0.0)	12)					
								World Heal

### **Evidence: mortality**

Survival benefit clear for continuous KMC. Insufficient evidence for intermittent KMC.

									- "
1.1.2 Intermittent KMC									Quality
Boo 2007	1	65	1	63	12.5%	0.97 [0.06, 15.16]	-		
Ghavane 2012	0	68	0	68		Not estimable			
Kadam 2005	1	44	1	45	12.2%	1.02 [0.07, 15.85]	-	-	
Rojas 2003	2	33	1	27	13.6%	1.64 [0.16, 17.09]		•	⊕⊕⊕0
Suman 2008	1	103	5	103	61.7%	0.20 [0.02, 1.68]			MODERATE
Subtotal (95% CI)	100	313		306	100.0%	0.59 [0.19, 1.81]			100 200 000 000 000
Total events	5		8						
Heterogeneity: Chi <sup>2</sup> = 2	2.00, df=	3 (P = 0.	.57);  ²=	0%					
Test for overall effect: 2	Z = 0.92 (	P = 0.36	)						
1.1.3 Continuous KMC									
Cattaneo 1998	3	149	3	136	8.3%	0.91 [0.19, 4.45]			
Charpak 1997	6	364	10	345	27.3%	0.57 [0.21, 1.55]	-	-	
Worku 2005	14	62	24	61	64.3%	0.57 [0.33, 1.00]	-		$\oplus \oplus \oplus \oplus$
Subtotal (95% CI)		575		542	100.0%	0.60 [0.38, 0.96]	•		HIGH
Total events	23		37						
Heterogeneity: Chi <sup>2</sup> = 0	0.31, df=	2 (P = 0.	.86); I <sup>z</sup> =	0%					
Test for overall effect: 2	Z = 2.13 (	P = 0.03	)						
							1	W.CLASSISPITION _	ld Health

### **Evidence: severe infection**

# KMC reduces risk of infection in small babies by 44% compared with conventional newborn care

	KMC	:	Contr	rol		Risk Ratio	Risk Ratio	0
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	Quality
1.5.1 Intermittent							0.771	
Ali 2009	3	58	10	56	12.4%	0.29 [0.08, 1.00]	-	
Boo 2007	2	56	1	62	1.2%	2.21 [0.21, 23.76]	· · · · · · · · · · · · · · · · · · ·	
Eka Pratiwi 2009	1	48	3	45	3.8%	0.31 [0.03, 2.90]	•	T T
Kadam 2005	6	44	8	45	9.6%	0.77 [0.29, 2.03]		⊕⊕⊕O
Rojas 2003	5	33	8	27	10.7%	0.51 [0.19, 1.38]	-	MODERATE
Suman 2008	4	103	15	103		0.27 [0.09, 0.78]	-	0.0000000000000000000000000000000000000
Subtotal (95% CI)		342		338	55.9%	0.45 [0.28, 0.73]	•	
Total events	21		45					
Heterogeneity: Chi²=	= 4.46, df=	5 (P=	0.48); I2:	= 0%				
Test for overall effect	: Z = 3.22 (	P = 0.0	001)					
4 E 3 Continuous								0000
1.5.2 Continuous							_	⊕⊕00
Charpak 1997	26	343 343	35	320 <b>320</b>				LOW
Subtotal (95% CI)		343		320	44.1%	0.69 [0.43, 1.12]	$\blacksquare$	
Total events	26		35					
Heterogeneity: Not ap		n 0.4						
Test for overall effect	.∠=1.48 (	P = 0.1	4)					
Total (95% CI)		685		658	100.0%	0.56 [0.40, 0.78]	•	⊕⊕⊕⊕
Total events	47		80				Ť	HIGH
Heterogeneity: Chi <sup>2</sup> =		6 (P =		= 0%				IIIGII
Test for overall effect				- 0 /0			0.01 0.1 1 10 100	
Test for subgroup dif			7000 V 7	1 (P =	0.21) [2=	: 35.3%	Favours KMC Favours control	1692
rection capqicap an		0111	1.00, 41	. ,.	0.217,1	00.070		World He
								Organizat
,								

# **Evidence:** hypothermia


KMC reduces risk of hypothermia in small babies by 66% compared with conventional newborn care

Intermittent						Quality
Ali 2009	1/58	10/56		8.6 %	0.10 [ 0.01, 0.73 ]	Quanty
Elca Prztiwi 2009	13/48	21/45	•	28.5 %	0.58 [ 0.33, 1.02 ]	
Ghavane 2012	1/68	0/68	-	4.1 %	3.00 [ 0.12, 72.37 ]	
Kadam 2005	10/44	21/45	-	27.1 %	0.49 [ 0.26, 0.91 ]	
Rojas 2003	1/33	5/27	-	82 %	@16[@0 <b>7</b> , 1.32]	⊕⊕⊕⊕
Suman 2008	6/103	38/103		23.4 %	0.16 [ 0.07, 0.36 ]	HIGH
Subtotal (95% CI)	354	344		100.0 %	0.34 [ 0.17, 0.67 ]	
Total events: 32 (KMC), 95 (Co	ontrol)					
Heterogeneity: Tau <sup>2</sup> = 0.35; CI	$\dot{n}^2 = 12.15, df = 5$	$(P = 0.03); 1^2 = 59\%$				
Test for overall effect: $Z = 3.12$	(P = 0.0018)					



### **Evidence: exclusive breastfeeding**

# KMC increases exclusive breastfeeding by 20% compared with conventional newborn care



### Benefits far beyond temperature maintenance

- Skin to skin contact promotes breastfeeding by effects both on mother and baby
- Lower infections perhaps due to reduced harmful exposure, microbiome, exclusive breastfeeding
- Reduced stress in the baby
- Increased bonding between mother and the baby
- Increased maternal efficacy and confidence in caring for her small baby



## Evidence gaps: key research priorities

- How can facility based initiation of effective KMC for stable small babies be scaled up?
- Can community-based initiation of KMC reduce neonatal mortality of clinically stable small babies?
- Does initiation of KMC immediately after birth, even for unstable babies, improve survival?



### **New WHO coordinated research**

- Learning how to implement KMC at scale to reach a population coverage of at least 80% (ongoing)
- Efficacy of home-initiation of KMC in reducing neonatal and infant mortality (ongoing, 25% enrolled)
- Efficacy of KMC initiated immediately after birth in reducing neonatal mortality (will be initiated in early 2017)



## KMC scale up study

- In Ethiopia and India, 7 populations of about a million each in different geographic regions
- Understanding barriers to implementation and addressing them systematically
- Accurate weighing of all newborns, referral, implementing KMC in health facilities, supporting continued KMC at home
- Independent population-based evaluation of coverage



## **Home-initiated KMC study**

- Individually randomized controlled trial in India. Sample size 10,500
- Low birth weight infants <48 hours old, born at home or discharged from health facilities without KMC
- Families allocated to intervention group supported to provide skin to skin contact, exclusive breastfeeding
- Primary outcome mortality to 1 and 6 months of age
- Early learnings: almost universal acceptance, average KMC duration about 9.5 hours per day achieved.



## **Immediate KMC study**

- Individually randomized controlled trial: hospitals in Ghana,
  India, Malawi, Nigeria and Tanzania. Sample size 4,200
- Newborns <1.8 kg will be allocated to intervention or control group</li>
- Those allocated to intervention will receive skin to skin care starting immediately after birth, and continued thereafter
- Those allocated to control will receive conventional care until considered stable, KMC will be initiated after that
- Primary outcome neonatal mortality



### **Conclusions**

- KMC is effective in improving survival, reducing infection, reducing hypothermia and improving breastfeeding
- Evidence of benefits only in studies conducted in hospitals
- Most previous studies initiated KMC only after the newborns were stable, average age at initiation >3 days
- Coverage of KMC remains low globally
- New research will address barriers to scale up, and evaluate efficacy in the period of greatest risk

